Introduction
============

Previous studies reported genotype-associated variations in both brain functions and physiology for a common single nucleotide polymorphism (SNP) in the catechol-*O*-methyltransferase (COMT) gene, leading to a substitution of valine (*Val*) to methionine (*Met*) at the codon 158 on chromosome 22q11 (*Val*158*Met*; Goldberg and Weinberger, [@B13]). For example, homozygous carriers of the *Val*-allele performed worse in executive and memory tasks than carriers of the *Met*-allele (Egan et al., [@B8]; Meyer-Lindenberg et al., [@B32]; Raz et al., [@B37]).

This differential cognitive performance might depend on a higher activity of the *Val*-encoded COMT enzyme (Lotta et al., [@B23]), playing a unique role for degradation of dopamine in the prefrontal cortex (PFC) (Mattay et al., [@B27]). Due to higher dopamine turnover in *Val/Val*-homozygotes, these individuals may exhibit less dopamine availability and therefore less efficient DA-dependent signaling in the PFC (Diaz-Asper et al., [@B6]; Lindenberger et al., [@B22]). Moreover, the impact of COMT genotype on cognition is supposed to magnify during late adulthood (Diaz-Asper et al., [@B6]; Lindenberger et al., [@B22]). For example, Nagel et al. ([@B35]) reported a clear advantage in cognitive performance of *Met*-carriers in old, but not in young participants. However, negative results have been reported as well (Potter et al., [@B36]), and the impact of COMT genotype on cognition is still a matter of debate (Barnett et al., [@B2]; Goldman et al., [@B14]).

Potential interactions between genetic phenotype and environmental factors have been suggested that render neurons more or less vulnerable to aging processes and neurodegenerative changes (Mattson et al., [@B29]; Lindenberger et al., [@B22]). For example, COMT genotype has been linked with the inter-individual cognitive response to extrinsic manipulation: Cognitive performance, in this case working memory, was found to be improved in *Val/Val*-carriers after pharmacologically induced dopamine release by oral amphetamine administration, whereas performance in *Met/Met*-carriers was decreased at high working memory load (Mattay et al., [@B27]). This genotype--drug interaction was also evident in functional magnetic resonance imaging (fMRI) during working memory tasks in the same study, where *Val/Val*-carriers showed a more efficient activation after amphetamine administration, which was similar to the activation seen in *Met/Met*-carriers after placebo, and vice versa (Mattay et al., [@B27]). Similarly, when using a behavioral manipulation, Loughead et al. ([@B24]) could demonstrate that *Val/Val*-carriers were more sensitive to a smoking abstinence challenge than *Met*-carriers, with respect to working memory performance and PFC activation.

In a previous interventional study of our group, we showed that caloric restriction (CR) improved memory performance in healthy elderly subjects (Witte et al., [@B44]). In that study, CR-associated increases in memory performance appeared to be correlated with changes in insulin signaling and inflammatory activity. Potential interactions with COMT genotype were not assessed.

The aim of the current study was to determine whether the response to the dietary intervention with regard to cognition was modulated by COMT *Val/Met*-allele carrier status. To address this question, we *post hoc* assessed COMT *Val*158*Met* genotype of subjects of the two intervention groups of the preceding study (Witte et al., [@B44]).

Materials and Methods
=====================

Subjects
--------

Thirty-nine healthy normal-to-overweight elderly subjects who completed a dietary intervention period in a previous study (Witte et al., [@B44]) were considered for genotyping.

Briefly, subjects included in the original study were stratified into three groups. One group was instructed to reduce caloric intake aiming at a reduction of 30% compared to previous habits (CR, *n* = 20), over a period of 3 months. Minimal caloric intake was set to 1.200 kcals/day to avoid cognitive problems due to malnutrition. Another group was instructed to increase the relative amount of unsaturated fatty acid (UFA, *n* = 20) intake about 20% compared to previous habits, over a period of 3 months. The quantity of total fat intake was intended to remain unchanged. Participants of the two intervention groups were guided by experienced dieticians. The third group was instructed not to change dietary habits (control, *n* = 10), those subjects were not genotyped in the present study that aimed at examining gene--environment interactions. Demographic and anthropometric data, as well as details on dietary compliance have been reported elsewhere (see Witte et al., [@B44]). One subject of the CR group did not complete the interventional study (drop-out). Three subjects had to be excluded due to technical problems during genotyping (2 female and 1 male); 1 additional female did not consent to genotyping, leaving 35 subjects (CR: *n* = 18, UFA: *n* = 19) for further analysis, see also Figure [1](#F1){ref-type="fig"}.

![**Number of subjects included in the interventional study and genetic analyses**. Subjects of the intervention groups underwent either Caloric restriction (CR) or enhancement of unsaturated fatty acids (UFA).](fnagi-02-00146-g001){#F1}

Before and after the intervention, subjects were tested on cognitive performance using parallel German versions of the Rey Auditory Verbal Learning Task (AVLT; Helmstaedter and Kurthen, [@B16]; Strauss et al., [@B42]). In short, subjects were asked to learn and recall as many words as possible out of a list of 15 words. After a delay of 30 min, subjects had to recognize these words in a recognition trial, resulting in raw memory scores, as described elsewhere (Witte et al., [@B44]). The primary outcome measure "memory score" was the number of retrieved words after adjusting for false-positives (Hochhaus, [@B17]; Helmstaedter and Kurthen, [@B16]; Strauss et al., [@B42]). Secondary outcome measures were total number of retrieved words without adjustment, and total number of false-positive errors.

Subjects did also complete trail making tests (TMT) A and B (Reitan and Herring, [@B38]), and forward/backward digit span (WMS-R, Markowitsch and Härting, [@B25]). In addition, all subjects filled in a 7 day custom-made dietary record to assess dietary habits. Fasting blood samples were collected in the morning to determine levels of insulin, glucose, lipid profile (triglycerides, cholesterol, LDL, HDL), inflammatory markers \[high sensitive C-reactive protein (hsCRP) and tumor-necrosis factor (TNF)-alpha\], and neurotrophins \[brain-derived neurotrophic factor (BDNF) and insulin-like growth factor 1 (IGF-1)\]. Memory scores of subjects of the CR group were significantly higher after the intervention, whereas scores of the other two group did not change significantly \[ANOVA~RM~ *F*~(2,\ 46)~ = 5.42, *P* = 0.008; *post hoc* paired *t*-test *t*~(18)~ = 4.73, *P* = 0.0002; published in Witte et al., [@B44]\].

All participants provided written informed consent and received reimbursement after participation. The research protocol was approved by the Ethics Committee of the University Hospital of Münster.

Genotyping
----------

Genomic DNA was extracted from whole blood using a DNA blood mini-kit (Quiagen) for sequencing of COMT *Val*158*Met* genotype. We used genebank sequences[^1^](#fn1){ref-type="fn"} to identify the common coding variant in the COMT gene, a G→A polymorphism responsible for the *Val*158*Met* substitution on chromosome 22q11 (Nagel et al., [@B35]). We designed sequencing primers (primer3)[^2^](#fn2){ref-type="fn"} (COMT-F GGGGCCTACTGTGGCTACTC; COMT-R GGTTTTCAGTGAACGTGGTG) resulting in a 174 bp polymerase chain reaction (PCR) product. Total volume of amplification reactions was 50 μl, containing 4 μl of DNA material (DNA concentration 34 ng/μl), 5 μl of each primer, 1 μl dNTP (Desoxyribonukleosidtriphosphate), 5 μl PCR-buffer (Quiagen) and 0.2 μl of Hot Start Taq Polymerase (Quiagen GmbH, Hilden, Germany). PCR cycling conditions comprised an initial denaturation for 15 min at 95°C, followed by 30 cycles of 94°C for 45 s, 59°C for 45 s, 72°C for 45 s and a final extension at 72°C for 10 min. PCR products were electrophoresed on a 2.5% agarose gel stain (Biozym LE Agarose; Biozym Scientific GmbH) and sequencing was completed using the Big Dye Terminator 3.1 chemistry on a 3730 DNA-Analyzer (Applied Biosystems, Darmstadt, Germany).

Based on their *Val*--*Met*-allele carrier status, participants were stratified into two genotype groups: homozygous *Val/Val*-carriers (*n* = 6) vs. one or two *Met*-allele carriers (*n* = 29), similar to previous studies (Mattay et al., [@B27]; Loughead et al., [@B24]).

Statistical analysis
--------------------

To detect significant differences in the AVLT memory score with regard to genotype at baseline, unpaired *t*-tests were calculated with dependent variable "memory score" and between-subjects factor "COMT *Val*158*Met* genotype" (*Val/Val*-carriers vs. *Val/Met*- or *Met/Met*-carriers). Secondary outcome measures (additionally AVLT measures, TMT A and B, digit span forward and backward), as well as demographic parameters and peripheral blood measures were compared between "genotype" groups by unpaired *t*-tests or non-parametric tests as appropriate.

To assess significant gene × diet interactions, ANOVA~RM~ were conducted with repeated factor "time" (AVLT memory scores at baseline vs. after intervention) and between-subjects factor "COMT *Val*158*Met* genotype" (*Val/Val*-carriers vs. *Val/Met*- or *Met/Met*-carriers) in the two dietary interventions group separately (CR, UFA). Unpaired *t*-tests (two-tailed) were calculated *post hoc* to detect significant differences in diet-induced memory changes. Additionally, ANOVA~RM~ or non-parametric tests were calculated with secondary outcome parameters as appropriate.

Significance was set at *p* = 0.05, all data are presented as mean with standard error of the mean, unless indicated otherwise.

Results
=======

Genetic analysis of COMT *Val*158*Met* genotype revealed a distribution of 6 *Val/Val*-carriers (CR: *n* = 3, UFA: *n* = 3) and 29 *Met*-carriers (CR: *n* = 13, UFA: *n* = 14). Demographic characteristics (sex, age, BMI, education) did not differ significantly with regard to genotype (*p* \> 0.05); see Table [1](#T1){ref-type="table"} for details.

###### 

**Demographic characteristics and fasting serum levels of COMT ***Val***158***Met*** genotype groups, dependent on intervention group and allelic variant**.

                                                   COMT *Val*158*Met* genotype                                                                                                 
  ------------------------------------------------ ----------------------------- ----------------------- ----------------------- ----------------------- --------------------- -----------------------
  **CHARACTERISTICS**                                                                                                                                                          
  *n*                                              3                             3                       6                       15                      14                    29
  Women, no.                                       1                             2                       3                       8                       8                     14
  Age, years ± SD (minimum/maximum)                56.3 ± 6 (53--63)             61 ± 9 (52--70)         58.7 ± 7 (52--70)       60.3 ± 8 (50--72)       62.4 ± 8 (51--79)     61.8 ± 8 (50--79)
  Body mass index, kg/m^2^ ±SD (minimum/maximum)   30.8 ± 2 (28.7--32.8)         23.9 ± 2 (23.9--26.4)   27.3 ± 4 (23.9--32.8)   29.7 ± 4 (23.7--39.3)   27 ± 2 (23.7--30.6)   28.4 ± 4 (23.7--39.3)
  Education, years ±SD (minimum/maximum)           14 ± 2 (13--16)               14 ± 2 (13--16)         14 ± 2 (13--16)         16.3 ± 6 (10--30)       15.7 ± 5 (10--23)     15.8 ± 5 (10--30)
  **FASTING SERUM LEVELS, MEAN** ± **SD**                                                                                                                                      
  Triglyceride, mg/dL                              183 ±80                       110.7 ±38               146.8 ±69               188.2 ± 116             140.2 ±60             167.9 ±98
  Cholesterol, mg/dL                               218.3 ±34                     231.7 ± 14              225 ±25                 257.3 ±60               244.9 ±34             252.1 ±51
  HDL cholesterol, mg/dL                           54.3 ± 14                     73.3 ± 18               63.8 ± 18               57.3 ± 15               58.7 ± 16             57.9 ± 15
  LDL cholesterol, mg/dL                           127.4 ±23                     136.2 ±23               131.8 ±21               162.4 ±49               158.1 ±32             160.6 ±42
  Insulin, mU/L                                    16.6 ± 6.1                    6 ± 3.6                 11.3 ±7.3               15.2 ± 15               10.7 ± 4.4            13.3 ± 12.1
  Glucose, mg/dL                                   101.3 ±1.2                    91 ±9                   96.2 ±8                 104.7 ±26               101.5 ± 10            103.4 ±20
  BDNF, pg/mL                                      1220 ± 277                    1183 ± 136              1202 ± 196              1102 ± 351              1251 ± 333            1165 ± 345
  IGF-1, ng/mL[\*](#tfn1){ref-type="table-fn"}     107.3 ±34                     89.3 ±7                 98.3 ±24                141.4 ±34               123.5 ±55             133.1 ±45
  hs nbCRP, pg/mL                                  0.13 ± 0.06                   0.38 ± 0.3              0.26 ± 0.2              0.42 ± 0.8              0.21 ± 0.2            0.33 ± 0.6
  TNF-alpha, pg/mL                                 1.14 ±1.5                     2.8 ± 4.3               1.99 ±3                 1.8 ±1.6                3.9 ± 2.7             2.7 ± 2.4

*CR, caloric restriction; UFA, unsaturated fatty acids*.

*\*Only IGF-1 concentrations were significantly different between genotype groups at baseline (Val/Val vs. Met; p = 0.02)*.

Effects of genotype at baseline
-------------------------------

There was a significant difference between memory scores of the AVLT at baseline when comparing COMT *Val*158*Met* genotypes (*t*-test; *t*~(1,\ 33)~ = 4.8, *p* \< 0.001; Figure [2](#F2){ref-type="fig"}), namely that *Val/Val*-carriers performed significantly poorer compared to *Met* carriers.

In contrast, no significant genotype-dependent differences were found regarding executive functions and working memory (Trail Making Test A and B, digit span forward and backward; *t*-tests, all *p* \> 0.05). Note that the two dietary interventions did not influence these tests in the initial study (Witte et al., [@B44]).

![**Baseline memory scores according to COMT *Val*158*Met* genotype**. Note that *Val/Val*-carriers had significant lower values than carriers of at least one *Met*-allele. \*\*\*, *p* = 0.001; according to unpaired *t*-test. Circles indicate individual values, solid lines indicate the mean.](fnagi-02-00146-g002){#F2}

There were no differences between genotype groups in anthropometric data (age, education, BMI) or fasting serum parameters (insulin, glucose, triglycerides, cholesterol, HDL, LDL, hsCRP, BDNF, TNF-alpha; Table [1](#T1){ref-type="table"}), except for IGF-1: *Val/Val*-carriers had significantly lower concentrations at baseline than *Met*-carriers (Table [1](#T1){ref-type="table"}, Mann--Whitney test, *p* = 0.02). This difference persisted after the intervention, namely that *Val/Val*-carriers again showed lower IGF-1 concentrations than *Met*-carriers (Mann--Whitney test, *p* = 0.02).

Gene × diet interactions
------------------------

In the CR group, there was a significant COMT genotype × time interaction \[repeated measures analysis of variance (ANOVA~RM~), *F*~(1,\ 16)~ = 14.9, *p* = 0.001; Figure [3](#F3){ref-type="fig"}\]. The CR-induced improvement of memory score was considerably greater in COMT *Val/Val*-carriers than in *Met*-carriers, so that memory scores of both genotype groups were no longer significantly different from each other after the intervention (*post hoc* *t*-test, *p* \> 0.05); however *t*-test of changes in memory score failed to reach significance between groups (*p* = 0.15).

![**Memory scores according to COMT *Val*158*Met* genotype pre- vs. post-caloric restriction (CR)**. Note that *Val/Val*-carriers (dashed line) nearly reached baseline levels of carriers of at least one *Met*-allele (gray line) after CR. \*\*\*, *p* = 0.001; \*\*\*, according to ANOVA~RM~. Error bars indicate standard error (SE).](fnagi-02-00146-g003){#F3}

Likewise in the UFA-group, ANOVA~RM~ detected a significant interaction effect of COMT genotype × time (*F*~(1,\ 15)~ = 6.9, *p* = 0.019; Figure [4](#F4){ref-type="fig"}). *Post hoc* *t*-tests of changes in memory score showed that *Val/Val*-carriers experienced significantly greater improvements due to the intervention than *Met*-carriers (*t*~(1,\ 15)~ = −2.6, *p* = 0.019).

![**Memory scores according to COMT *Val*158*Met* genotype pre- vs. post-enhancement of unsaturated fatty acids (UFA)**. Note that *Val/Val*-carriers (dashed line) nearly reached baseline levels of carriers of at least one *Met*-allele (gray line) after UFA enhancement. \*, *p* = 0.019; \*, according to ANOVA~RM~. Error bars indicate standard error (SE).](fnagi-02-00146-g004){#F4}

No significant differences were detected for genotype groups with regard to changes in anthropometric data or fasting serum parameters (see above for details) due to the intervention (all *p\'s* \> 0.05).

However, an interesting trend emerged for markers of inflammation: Diet-associated reductions in TNF-alpha levels after the intervention were more pronounced in *Val/Val*-carriers (Figure [5](#F5){ref-type="fig"}), however ANOVA~RM~ failed to reach significance.

![**Differences in TNF-alpha levels pre- vs. post-dietary intervention according to COMT Val158Met genotype**. Note that *Val/Val*-carriers exhibited greater reductions of TNF-alpha than *Met*-carriers, however analysis failed to reach significance. Error bars indicate standard error (SE).](fnagi-02-00146-g005){#F5}

Considering IGF-1, there was an overall significant increase after the intervention over the entire study group (Wilcoxon-Ranks test, *p* = 0.021), which was not significantly different with regard to genotype group (*p* \> 0.05).

Discussion
==========

Our study provides first-time evidence that the cognitive response to dietary interventions is dependent on COMT *Val*158*Met* genotype. At baseline, *Val/Val*-carriers had significantly lower memory scores compared to *Val/Met*-carriers and *Met/Met*-carriers, which is in line with previous studies on cognitive performance (e.g., de Frias et al., [@B5]; Bertolino et al., [@B3]). Overall improvements in memory score due to dietary intervention were then significantly greater in *Val/Val*-carriers compared to *Met*-carriers, leading to comparable memory scores in the genetic groups after the intervention.

Comt genotype and cognition
---------------------------

Our findings of lower memory performance in *Val/Val*-carriers at baseline are consistent with several previous reports, summarized in a recent meta-analysis (Raz et al., [@B37]). For example, in a longitudinal sample of 286 men, *Met/Met*-carrier status was associated with better episodic and semantic memory (de Frias et al., [@B5]). Similarly using an fMRI recognition memory paradigm, Bertolino et al. ([@B3]) found poorer performance and differential activation in memory-related brain areas such as the hippocampus and ventrolateral PFC in *Val*-carriers compared to *Met/Met*-carriers. Notably, both studies distinguished carriers of one or two *Val*-allele vs. homozygous *Met/Met*-carriers; but brain activation patterns rather depict a dose-dependent relationship of *Met*-alleles in these studies (see, e.g., Figures 2 and 3 in Bertolino et al., [@B3]). Several other behavioral and fMRI studies found, similar to our results, a clear distinction between *Val/Val* vs. *Met*-allele carriers (Mattay et al., [@B27]; Enoch et al., [@B10]; Loughead et al., [@B24]; Krach et al., [@B20]).

Considering tasks probing executive functions, working memory, and attention, we did not find significant differences dependent on COMT genotype, similar to most (see, e.g., meta-analysis by Barnett et al., [@B2]), but not all studies (Egan et al., [@B8]; Mier et al., [@B33]). Thus, there is still considerable debate about the impact of COMT genotype on specific cognitive functions, and future studies using larger number of subjects will have to resolve this issue.

The COMT gene is widely distributed in the brain (Hong et al., [@B19]), including prefrontal and mesotemporal/hippocampal areas which are strongly linked with memory performance (Shing et al., [@B40]). Notably, COMT is thought to be crucially involved in the regulation of dopamine flux in the PFC, due to the minimal role of other degrading pathways as, for example, the dopamine transporter in this area (Lewis et al., [@B21]; Mazei et al., [@B31]; Morón et al., [@B34]). Therefore, the higher enzymatic activity of the COMT enzyme encoded by the *Val*-allele (Lotta et al., [@B23]) induces lower brain dopamine levels compared to *Met*-carriers especially in prefrontal areas (Diaz-Asper et al., [@B6]), which could account for differences in prefrontal neuronal processing. Notably, decreases in memory performance during late adulthood are thought to depend on impairments in both prefrontal and mesotemporal/hippocampal processing (Shing et al., [@B40]), therefore COMT-dependent, less efficient prefrontal dopamine signaling could lead to deficits in recall and delayed recognition in *Val/Val*-carriers.

Moreover, the effect of COMT genotype on cognitive processing *per se* is thought to be magnified with advancing age (Lindenberger et al., [@B22]; Nagel et al., [@B35]). Nagel and colleagues used a test of executive function, the WCST, in young and in elderly individuals to show that the effect of COMT *Val/Val*-carrier status is significantly more disadvantageous in old than in young age. Their findings support the hypothesis that optimal cognitive function is associated with optimal brain dopamine levels (Lindenberger et al., [@B22]; Nagel et al., [@B35]). As normal aging is linked with an overall decline in dopaminergic neuromodulation (Volkow et al., [@B43]; Backman et al., [@B1]; Erixon-Lindroth et al., [@B11]), individuals with low dopamine levels even at young age, such as *Val/Val*-carriers, might be more vulnerable to these adverse effects than others. At the same time, these individuals may benefit more from dopamine-enhancing strategies, a hypothesis that already received experimental support (e.g., Mattay et al., [@B27]): In that study, due to dopamine-enhancing amphetamine administration, *Val/Val*-carriers showed an improvement in working memory tasks as well as more efficient brain activation using fMRI, whereas carriers of at least one *Met*-allele performed worse after the same drug dosage (Mattay et al., [@B27]). Likewise, *Val/Val*-carriers showed a significant improvement of working memory and other cognitive tasks in response to the COMT-inhibitor tolcapone (Giakoumaki et al., [@B12]). Similar results were also found for a behavioral intervention testing the response to a smoking abstinence challenge in heavy smokers (Loughead et al., [@B24]). Here, *Val/Val*-carriers were more sensitive to an overnight smoking cessation than *Met*-carriers, demonstrated by stronger prefrontal blood oxygen level-dependent (BOLD)-signals and by slower reaction time during n-back tasks at smoking abstinence in *Val/Val*-carriers only (Loughead et al., [@B24]).

Gene × diet interactions
------------------------

In line with these studies, we found a better cognitive response to dietary interventions for *Val/Val*-carriers compared to carriers of one or two *Met*-alleles: The former experienced a considerably greater improvement of memory scores after CR and after UFA enhancement.

Both CR and UFA may improve neuronal plasticity and cognitive functions such as memory via several pathways, including on the one hand direct augmentation of prefrontal dopamine release, e.g., via glucoregulatory processes (Ritter et al., [@B39]), or via beneficial effects of diet-induced neurotrophic factor release on dopaminergic neurons (Mattson et al., [@B28]).

Moreover, CR and UFA may activate other plasticity-enhancing mechanisms, such as increase in membrane fluidity, improvement of glucose/insulin-dependent second messenger cascades, and down-regulation of inflammatory activity (see, e.g., Mattson et al., [@B28]; Zhao et al., [@B46]; Gomez-Pinilla, [@B15]; Stranahan and Mattson, [@B41]; Witte et al., [@B44]). These processes may then compensate for the genotype-related deficits in cognition due to less dopaminergic neurotransmission in *Val/Val*-carriers. Considering inflammatory markers, our results of stronger diet-associated reductions in TNF-alpha levels in *Val/Val*-carriers lend some experimental support to this hypothesis.

A consistent reduction of IGF-1 levels in *Val/Val*-carriers was noted compared to *Met*-carriers before and after the intervention, in line with previous studies (Hong et al., [@B18]). However we did not find genotype-dependent differences in the response of IGF-1 to the CR intervention, or regarding BDNF, glucose or insulin. These negative findings may be due to limited power because of the small sample size. Further studies with larger sample sizes are needed to explore these suggested mechanisms in more detail.

Taken together, we hypothesize that diet-associated beneficial processes were able to move the genotype-related lower memory scores in our *Val/Val*-carriers toward the performance of *Met*-carriers, underlining that the "at risk" genotype with regard to brain function takes greater advantage of a behavioral intervention. Data from another common learning-relevant SNP which has been linked to memory performance and hippocampal processing, BDNF *Val*66*Met* (Egan et al., [@B9]), support this idea: Carriers of the *Met*-allele, associated with lower BDNF-levels, experienced greater advantages due to exercise than carriers of the *Val*-allele (Mata et al., [@B26]). A larger gene--lifestyle interaction for the "at risk" carriers with regard to cognition have also been observed for other learning-relevant genes, e.g., apo-lipoprotein E (APOE) (Dore et al., [@B7]), and "kidney and brain" (KIBRA) (Zhang et al., [@B45]). For example, the negative effect of diabetes on cognitive performance was found to be enlarged in carriers of the "at risk" APOE epsilon 4-alleles, compared to non-APOE epsilon 4 carriers (Dore et al., [@B7]). Smoking status has been shown to modulate cognitive functions in KIBRA T-allele carriers, considered as "at risk" genotype because of worse performance on executive tasks, but not in non-T-allele carriers (Zhang et al., [@B45]). Taken together, there is some evidence that homozygous "at risk"-allele carriers of specific plasticity-related polymorphisms (such as COMT *Val*158*Met*, or BDNF *Val*66*Met*) tend to better respond to lifestyle or pharmacological interventions.

Limitations
-----------

Several limitations have to be considered when interpreting our results. First, genotyping of the study was retrospective, therefore sample size was low, and not all subjects originally included in the study could be genotyped. Also, we did not assess other gene × gene interactions, which could have exerted influence on dopaminergic neurotransmission. For example, the impact of genetic variations in the genes encoding the dopamine transporter, the dopamine D2 receptor, as well as additional COMT locations (Meyer-Lindenberg et al., [@B32]), warrant to be determined in future research.

Conclusions
-----------

In this retrospective assessment of COMT *Val*158*Met* genotype in healthy elderly subjects, we found first-time evidence that the "at risk" genotype *Val/Val* might benefit more from dietary modifications with regard to cognitive functions than *Met*-allele carriers. Our findings may help to explain inter-individual differences in the response to cognition-enhancing interventions, and may constitute a first step toward the development of individualized therapies in future research (Mayor, [@B30]). Further studies are now needed to help clarifying the mechanisms underlying these effects, which will allow to specifically develop new agents and/or lifestyle interventions targeting the identified mechanisms, with the ultimate aim to preserve cognitive functions until old age (Corneveaux et al., [@B4]).
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